Tonix Pharmaceuticals Presents Data on TNX-801 Mpox Vaccine
Tonix Pharmaceuticals Holding Corp. presented data on TNX-801, a live virus vaccine investigational candidate, at the World Vaccine Congress–Europe 2025.
TNX-801 is designed to provide durable protection against mpox and smallpox, demonstrating favorable safety, immunogenicity, and long-term protection in multiple preclinical models.
Data supports the advancement of TNX-801 toward clinical development. A copy of the presentation, titled Safety, Durability and Protection of a Single-Dose TNX-801 Mpox Vaccine, is available on the Tonix website.
TNX-801 demonstrated favorable safety, immunogenicity, and long-term protection in multiple preclinical models
Author's summary: Tonix Pharmaceuticals presented data on TNX-801 vaccine.
More News
- Preview | Sunderland vs Wolves
- Courtheyn studies global solidarity and community resilience in Colombia
- | Helly Hansen Odin Everdown Hooded Jacket | Review
- Samorost 3 is a weird journey into wonder that's now free on the Epic Games Store for mobile
- Golden Knights caught in ugly fallout less than 24 Hours after Carter Hart signing
- LPEA CEO Chris Hansen to speak at Democratic Club Meeting – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- The Ghost of Yotei map is a great tool, but choosing to not use it expands the world.
- Tipp GAA club to donate lotto earnings to help a family of a club member undergoing treatment
- "The Smashing Machine's" misfired punches - The Triangle
- The 11 Best Body-Swap Movies, Ranked | Features | Roger Ebert